New combo therapy aims to silence hepatitis b virus in hard-to-treat patients
NCT ID NCT07090759
First seen Jan 23, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This phase 3 trial tests a new drug called GST-HG141 (Neracorvir) added to standard antiviral pills for people with chronic hepatitis B who still have virus in their blood despite treatment. About 526 adults aged 18-70 who have been on antivirals for over a year will receive either the new drug or a placebo. The goal is to see if the combination can lower the virus to undetectable levels and improve control of the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shulan(Hangzhou) Hospital
RECRUITINGHangzhou, Zhejiang, 310011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.